Nothing Special   »   [go: up one dir, main page]

NO20060319L - 3,5-disubstituerte indazolforbindelser, farmasoytiske blandinger og fremgangsmater for a mediere eller inhibere celleproliferasjon - Google Patents

3,5-disubstituerte indazolforbindelser, farmasoytiske blandinger og fremgangsmater for a mediere eller inhibere celleproliferasjon

Info

Publication number
NO20060319L
NO20060319L NO20060319A NO20060319A NO20060319L NO 20060319 L NO20060319 L NO 20060319L NO 20060319 A NO20060319 A NO 20060319A NO 20060319 A NO20060319 A NO 20060319A NO 20060319 L NO20060319 L NO 20060319L
Authority
NO
Norway
Prior art keywords
compounds
cell proliferation
mediate
methods
inhibit cell
Prior art date
Application number
NO20060319A
Other languages
English (en)
Norwegian (no)
Inventor
Susan Elizabeth Kephart
Indrawan James Mcalpine
Siegfried Heinz Reich
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of NO20060319L publication Critical patent/NO20060319L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20060319A 2003-07-30 2006-01-20 3,5-disubstituerte indazolforbindelser, farmasoytiske blandinger og fremgangsmater for a mediere eller inhibere celleproliferasjon NO20060319L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US49147403P 2003-07-30 2003-07-30
US49207303P 2003-07-31 2003-07-31
PCT/IB2004/002441 WO2005009997A1 (fr) 2003-07-30 2004-07-19 Composes d'indazole 3,5 disubstitutes, compositions pharmaceutiques, et procedes pour medier ou inhiber la proliferation cellulaire

Publications (1)

Publication Number Publication Date
NO20060319L true NO20060319L (no) 2006-02-24

Family

ID=34108010

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20060319A NO20060319L (no) 2003-07-30 2006-01-20 3,5-disubstituerte indazolforbindelser, farmasoytiske blandinger og fremgangsmater for a mediere eller inhibere celleproliferasjon

Country Status (24)

Country Link
US (2) US7008953B2 (fr)
EP (1) EP1658284A1 (fr)
JP (1) JP3920914B2 (fr)
KR (1) KR20060030914A (fr)
AR (1) AR045143A1 (fr)
AU (1) AU2004259531A1 (fr)
BR (1) BRPI0413051A (fr)
CA (1) CA2532908A1 (fr)
CO (1) CO5650247A2 (fr)
EA (1) EA200600123A1 (fr)
EC (1) ECSP066335A (fr)
IL (1) IL172924A0 (fr)
IS (1) IS8214A (fr)
MA (1) MA27937A1 (fr)
MX (1) MXPA06001193A (fr)
NL (1) NL1026761C2 (fr)
NO (1) NO20060319L (fr)
OA (1) OA13196A (fr)
PA (1) PA8608201A1 (fr)
PE (1) PE20050330A1 (fr)
TN (1) TNSN06038A1 (fr)
TW (1) TW200521124A (fr)
UY (1) UY28442A1 (fr)
WO (1) WO2005009997A1 (fr)

Families Citing this family (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7008953B2 (en) * 2003-07-30 2006-03-07 Agouron Pharmaceuticals, Inc. 3, 5 Disubstituted indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation
EP1740184A1 (fr) * 2004-03-30 2007-01-10 Pfizer Products Incorporated Combinaisons d'inhibiteurs de transduction de signaux
WO2006024945A1 (fr) * 2004-09-03 2006-03-09 Pfizer Inc. Compositions pharmaceutiques contenant un inhibiteur des cdk
US20060116519A1 (en) * 2004-11-17 2006-06-01 Agouron Pharmaceuticals, Inc. Synthesis of 5-bromo-4-methyl-pyridin-3-ylmethyl)-ethyl-carbamic acid tert-butyl ester
WO2006054143A1 (fr) * 2004-11-17 2006-05-26 Pfizer Inc. Formes polymorphes de {5-[3-(4,6-difluoro-1h-benzimidazol-2-yl)-1h-indazol-5-yl]-4-methyl-pyridin-3-ylmethyl}-ethyl-amine
WO2006100627A1 (fr) 2005-03-21 2006-09-28 Koninklijke Philips Electronics N.V. Appareil de soins personnels a distributeur de fluide automatique
US8252945B2 (en) * 2005-04-13 2012-08-28 Ube Industries, Ltd. Protective agent for retinal neuronal cell comprising indazole derivative as active ingredient
WO2006130673A1 (fr) 2005-05-31 2006-12-07 Janssen Pharmaceutica, N.V. 3-benzoimidazolyl-pyrazolopyridines utilisees pour traiter des troubles dont la mediation est assuree par des kinases
JP2009523845A (ja) * 2006-01-23 2009-06-25 クリスタルゲノミクス インコーポレーテッド たんぱく質キナーゼの活性を阻害するイミダゾピリジン誘導体、これの製造方法およびこれを含む薬学組成物
EP2046774A1 (fr) * 2006-07-05 2009-04-15 Pfizer Products Inc. Dérivés de pyrazole utilisés en tant qu'inhibiteurs du cytochrome p450
JP2010500300A (ja) 2006-08-08 2010-01-07 サノフィ−アベンティス アリールアミノアリール−アルキル−置換イミダゾリジン−２，４−ジオン、それらの製造法、それらの化合物を含有する薬剤、およびそれらの使用
KR20100032886A (ko) * 2007-06-08 2010-03-26 아보트 러보러터리즈 키나제 억제제로서의 5-헤테로아릴 치환된 인다졸
US8648069B2 (en) 2007-06-08 2014-02-11 Abbvie Inc. 5-substituted indazoles as kinase inhibitors
MX2010001650A (es) * 2007-08-10 2010-08-02 Glaxosmithkline Llc Entidades quimicas biciclicas que contienen nitrogeno para el tratamiento de infecciones virales.
EP2025674A1 (fr) 2007-08-15 2009-02-18 sanofi-aventis Tetrahydronaphthaline substituée, son procédé de fabrication et son utilisation en tant que médicament
WO2009149837A1 (fr) * 2008-06-09 2009-12-17 Bayer Schering Pharma Aktiengesellschaft 4-(indazolyl)-1,4-dihydropyridines substituées et leurs procédés d’utilisation
TW201014822A (en) 2008-07-09 2010-04-16 Sanofi Aventis Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
US8394969B2 (en) 2008-09-26 2013-03-12 Merck Sharp & Dohme Corp. Cyclic benzimidazole derivatives useful as anti-diabetic agents
CA2741125A1 (fr) 2008-10-22 2010-04-29 Merck Sharp & Dohme Corp. Nouveaux derives de benzimidazole cycliques utiles comme agents anti-diabetiques
US8329914B2 (en) 2008-10-31 2012-12-11 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
US8697685B2 (en) 2008-11-20 2014-04-15 Glaxosmithkline Llc Chemical compounds
WO2010068601A1 (fr) 2008-12-08 2010-06-17 Sanofi-Aventis Hydrate de fluoroglycoside hétéroaromatique cristallin, ses procédés de fabrication, ses procédés d'utilisation et compositions pharmaceutiques le contenant
ES2835553T3 (es) 2009-08-10 2021-06-22 Biosplice Therapeutics Inc Inhibidores de indazol de la vía de señalización de Wnt y sus usos terapéuticos
CA2770320A1 (fr) * 2009-08-10 2011-02-17 Epitherix, Llc Indazoles utiles comme inhibiteurs de la voie de signalisation de wnt/beta-catenine et utilisations therapeutiques de ceux-ci
CN102482312A (zh) 2009-08-26 2012-05-30 赛诺菲 新颖的杂芳族氟代糖苷结晶水合物、含有这些化合物的药物和它们的用途
EP2515655B1 (fr) 2009-12-21 2015-08-05 Samumed, LLC 1h-pyrazolo[3,4-beta]pyridines et leurs utilisations thérapeutiques
WO2011106273A1 (fr) 2010-02-25 2011-09-01 Merck Sharp & Dohme Corp. Nouveaux dérivés benzimidazole cycliques utiles comme agents antidiabétiques
WO2011107494A1 (fr) 2010-03-03 2011-09-09 Sanofi Nouveaux dérivés aromatiques de glycoside, médicaments contenants ces composés, et leur utilisation
WO2011157827A1 (fr) 2010-06-18 2011-12-22 Sanofi Dérivés d'azolopyridin-3-one en tant qu'inhibiteurs de lipases et de phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
CN104672202B (zh) 2010-08-18 2017-07-28 萨穆梅德有限公司 作为联蛋白信号通路激活剂的二酮与羟基酮
WO2012078777A1 (fr) * 2010-12-09 2012-06-14 Amgen Inc. Composés bicycliques en tant qu'inhibiteurs de pim
US8809324B2 (en) 2011-03-08 2014-08-19 Sanofi Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
US8809325B2 (en) 2011-03-08 2014-08-19 Sanofi Benzyl-oxathiazine derivatives substituted with adamantane and noradamantane, medicaments containing said compounds and use thereof
WO2012120054A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés oxathiazine di- et tri-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation
EP2683699B1 (fr) 2011-03-08 2015-06-24 Sanofi Dérivés oxathiazine di- et tri-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation
US8895547B2 (en) 2011-03-08 2014-11-25 Sanofi Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
EP2766349B1 (fr) 2011-03-08 2016-06-01 Sanofi Dérivés d'oxathiazine substitués par des carbocycles ou des hétérocycles, leur procédé de préparation, médicaments contenant ces composés et leur utilisation
EP2683700B1 (fr) 2011-03-08 2015-02-18 Sanofi Dérivés d'oxathiazine tétra-substitués, leur procédé de fabrication, leur utilisation comme médicament ainsi que médicaments en étant pourvu et leur utilisation
EP2683701B1 (fr) 2011-03-08 2014-12-24 Sanofi Dérivés d'oxathiazine substitués par des groupes de benzyle-méthyles ou d'hétéro-méthyles, leur procédé de fabrication, leur utilisation comme médicament ainsi que médicaments en étant pourvu et leur utilisation
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2688886A1 (fr) 2011-03-22 2014-01-29 Amgen Inc. Composés d'azole utilisés en tant qu'inhibiteurs des pim
WO2013037390A1 (fr) 2011-09-12 2013-03-21 Sanofi Dérivés amides d'acide 6-(4-hydroxyphényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase
ME03332B (fr) 2011-09-14 2019-10-20 Samumed Llc Indazole-3-carboxamides et leur utilisation en tant qu'inhibiteurs de la voie de signalisation par wnt/ -caténine
WO2013045413A1 (fr) 2011-09-27 2013-04-04 Sanofi Dérivés d'amide d'acide 6-(4-hydroxyphényl)-3-alkyl-1h-pyrazolo[3,4-b] pyridine-4-carboxylique utilisés comme inhibiteurs de kinase
US9469606B2 (en) 2011-10-25 2016-10-18 The General Hospital Corporation Wnt/b-catenin inhibitors and methods of use
PH12017500997A1 (en) 2012-04-04 2018-02-19 Samumed Llc Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof
NZ741907A (en) 2012-05-04 2020-02-28 Samumed Llc 1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof
MX370487B (es) * 2013-01-08 2019-12-16 Samumed Llc Inhibidores de 3-(benzo-imidazol-2-il)-indazol de la senda de señalización de wnt y usos terapéuticos de los mismos.
CA2901671C (fr) 2013-02-22 2021-07-13 Samumed, Llc .gamma.-dicetones en tant qu'activateurs de la voie de signalisation wnt/.beta.-catenine
CA2958580C (fr) 2014-08-20 2023-10-24 Samumed, Llc Gamma-dicetones pour le traitement et la prevention des rides et du vieillissement de la peau
WO2016040193A1 (fr) 2014-09-08 2016-03-17 Samumed, Llc 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine et ses utilisations thérapeutiques
WO2016040185A1 (fr) 2014-09-08 2016-03-17 Samumed, Llc 2-1h-indazol-3-yl)-3h-imidazo[4,5-b]pyridine et ses utilisations thérapeutiques
WO2016040180A1 (fr) 2014-09-08 2016-03-17 Samumed, Llc 3-1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[3,4-c]pyridine et ses utilisations thérapeutiques
WO2016040190A1 (fr) 2014-09-08 2016-03-17 Samumed, Llc 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine et ses utilisations thérapeutiques
WO2016040188A1 (fr) 2014-09-08 2016-03-17 Samumed, Llc 3-3h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine et ses utilisations thérapeutiques
WO2016040181A1 (fr) 2014-09-08 2016-03-17 Samumed, Llc 3-1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine et ses utilisations thérapeutiques
WO2016040184A1 (fr) 2014-09-08 2016-03-17 Samumed, Llc 3-3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine et ses utilisations thérapeutiques
WO2016040182A1 (fr) 2014-09-08 2016-03-17 Samumed, Llc 2-(1h-indazol-3-yl)-1h-imidazo[4,5-c]pyridine et ses utilisations thérapeutiques
GB201511382D0 (en) 2015-06-29 2015-08-12 Imp Innovations Ltd Novel compounds and their use in therapy
US10329309B2 (en) 2015-08-03 2019-06-25 Samumed, Llc 3-(3H-imidazo[4,5-B]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
US10392383B2 (en) 2015-08-03 2019-08-27 Samumed, Llc 3-(1H-benzo[d]imidazol-2-yl)-1H-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
WO2017023993A1 (fr) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-indol-2-yl)-1h-pyrazolo[4,3-b]pyridines et leurs utilisations thérapeutiques
US10285982B2 (en) 2015-08-03 2019-05-14 Samumed, Llc 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof
WO2017023988A1 (fr) 2015-08-03 2017-02-09 Samumed, Llc. 3-(3h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines et leurs utilisations thérapeutiques
US10463651B2 (en) 2015-08-03 2019-11-05 Samumed, Llc 3-(1H-pyrrolo[3,2-C]pyridin-2-YL)-1H-indazoles and therapeutic uses thereof
WO2017023986A1 (fr) 2015-08-03 2017-02-09 Samumed, Llc 3-(1h-indol-2-yl)-1h-indazoles et leurs utilisations thérapeutiques
WO2017023972A1 (fr) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines et leurs utilisations thérapeutiques
WO2017024025A1 (fr) 2015-08-03 2017-02-09 Sunil Kumar Kc 3-(1h-pyrrolo[2,3-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines et leurs utilisations thérapeutiques
WO2017024004A1 (fr) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines et leurs utilisations thérapeutiques
US10350199B2 (en) 2015-08-03 2019-07-16 Samumed, Llc 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-indazoles and therapeutic uses thereof
WO2017024003A1 (fr) 2015-08-03 2017-02-09 Samumed, Llc 3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines et leurs utilisations thérapeutiques
US10285983B2 (en) 2015-08-03 2019-05-14 Samumed, Llc 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[3,4-B] pyridines and therapeutic uses thereof
US10166218B2 (en) 2015-08-03 2019-01-01 Samumed, Llc 3-(1H-indol-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof
US10206908B2 (en) 2015-08-03 2019-02-19 Samumed, Llc 3-(1H-pyrrolo[3,2-C]pyridin-2-YL)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof
US10226448B2 (en) 2015-08-03 2019-03-12 Samumed, Llc 3-(1H-pyrrolo[3,2-C]pyridin-2-yl)-1H-pyrazolo[3,4-B]pyridines and therapeutic uses thereof
WO2017023975A1 (fr) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-pyrrolo[2,3-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridines et leus utilisations thérapeutiques
WO2017040993A1 (fr) * 2015-09-03 2017-03-09 The Arizona Board Of Regents On Behalf Of The University Of Arizona Petites molécules inhibitrices de dyrk1a et leurs utilisations
WO2017079765A1 (fr) 2015-11-06 2017-05-11 Samumed, Llc Traitement de l'ostéoarthrite
AR108325A1 (es) 2016-04-27 2018-08-08 Samumed Llc Isoquinolin-3-il carboxamidas y preparación y uso de las mismas
AR108326A1 (es) 2016-04-27 2018-08-08 Samumed Llc Isoquinolin-3-il carboxamidas y preparación y uso de las mismas
MX2018014871A (es) 2016-06-01 2019-11-05 Samumed Llc Proceso de preparacion de n-(5-(3-(7-(3-fluorofenil)-3h-imidazo[4, 5-c]piridin-2-il)-1h-indazol-5-il)piridin-3-il)-3-metilbutanamida .
WO2018013430A2 (fr) 2016-07-12 2018-01-18 Arisan Therapeutics Inc. Composés hétérocycliques pour le traitement d'une infection à arenavirus
BR112019008061A2 (pt) 2016-10-21 2019-09-17 Samumed Llc métodos de uso de indazol-3-carboxamidas e seu uso como inibidores da via de sinalização de wnt/b-catenina
MA46696A (fr) 2016-11-07 2019-09-11 Samumed Llc Formulations injectables à dose unique prêtes à l'emploi
US10604514B2 (en) 2017-10-19 2020-03-31 Samumed, Llc 6-(5-membered heteroaryl)isoquinolin-3-yl carboxamides and preparation and use thereof
US10413537B2 (en) 2017-10-27 2019-09-17 Samumed, Llc 6-(5-membered heteroaryl)isoquinolin-3-yl-(5-membered heteroaryl) carboxamides and preparation and use thereof
US10653688B2 (en) 2017-10-27 2020-05-19 Samumed, Llc 6-(6-membered heteroaryl and aryl)isoquinolin-3-yl carboxamides and preparation and use thereof
WO2019089835A1 (fr) 2017-10-31 2019-05-09 Samumed, Llc Diazanaphthalèn-3-yl carboxamides, préparation et utilisation de ceux-ci
ES2945558T3 (es) 2018-02-23 2023-07-04 Biosplice Therapeutics Inc Indazol-3-carboxamidas sustituidas con 5-heteroarilo y preparación y uso de las mismas
WO2019241540A1 (fr) 2018-06-15 2019-12-19 Samumed, Llc Macrocycles contenant de l'indazole et utilisations thérapeutiques associées
WO2020150545A1 (fr) 2019-01-17 2020-07-23 Samumed, Llc DÉRIVÉS DE PYRAZOLE UTILISÉS COMME MODULATEURS DE LA VOIE DE SIGNALISATION WNT/β-CATÉNINE
WO2021168341A1 (fr) 2020-02-21 2021-08-26 Samumed, Llc Formes solides de 1-(5-(3-(7-(3-fluorophényl)-3h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)-n,n-diméthylméthanamine

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1376600A (en) 1971-02-15 1974-12-04 Agfa Gevaert Photographic developer compositions
FR2265739B1 (fr) 1974-03-29 1976-12-17 Ugine Kuhlmann
JPS5615287A (en) 1979-07-16 1981-02-14 Chugai Pharmaceut Co Ltd Pyrazoloindazole derivative and its preparation
JPS57109787A (en) 1980-12-26 1982-07-08 Chugai Pharmaceut Co Ltd Pyrazoloindazole derivative
JPS59228248A (ja) 1983-06-08 1984-12-21 Konishiroku Photo Ind Co Ltd 直接ポジ用ハロゲン化銀写真感光材料
JPS604184A (ja) 1983-06-23 1985-01-10 Chugai Pharmaceut Co Ltd ピラゾロインダゾ−ル誘導体
US4978603A (en) 1987-12-14 1990-12-18 Fuji Photo Film Co., Ltd. Image forming process comprising developing fine grain silver halide emulsion with a hydroquinone developer
US5208248A (en) 1991-01-11 1993-05-04 Merck Sharpe & Dohme, Ltd. Indazole-substituted five-membered heteroaromatic compounds
EP0494774A1 (fr) 1991-01-11 1992-07-15 MERCK SHARP & DOHME LTD. Composés hétéroaromatiques à 5 chaînons substitués par l'indazole
NZ243065A (en) 1991-06-13 1995-07-26 Lundbeck & Co As H Piperidine derivatives and pharmaceutical compositions
ZA951822B (en) 1994-12-23 1996-09-26 Glaxo Group Ltd Chemical compounds
EP0780386B1 (fr) 1995-12-20 2002-10-02 F. Hoffmann-La Roche Ag Inhibiteurs de métalloprotéases matricielles
EP0818442A3 (fr) 1996-07-12 1998-12-30 Pfizer Inc. Dérivés cycliques de sulfones comme inhibiteurs de métalloprotéinase et de la production du facteur de nécrose des tumeurs
HRP970371A2 (en) 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
JP2001518094A (ja) 1997-03-31 2001-10-09 デュポン ファーマシューティカルズ カンパニー Ｈｉｖプロテアーゼ阻害剤として有用なインダゾール−環式尿素
FR2767475A1 (fr) 1997-08-25 1999-02-26 Oreal Compositions de teinture des fibres keratiniques contenant des derives d'indazoles et procede
IL143870A0 (en) 1998-12-23 2002-04-21 Searle & Co Method of using a cyclooxygenase-2 inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
GB2345486A (en) 1999-01-11 2000-07-12 Glaxo Group Ltd Heteroaromatic protein tyrosine kinase inhibitors
YU54202A (sh) 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
KR100423899B1 (ko) 2000-05-10 2004-03-24 주식회사 엘지생명과학 세포 증식 억제제로 유용한 1,1-디옥소이소티아졸리딘을갖는 인다졸
US6897231B2 (en) 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
US7064215B2 (en) 2001-07-03 2006-06-20 Chiron Corporation Indazole benzimidazole compounds
FR2831536A1 (fr) 2001-10-26 2003-05-02 Aventis Pharma Sa Nouveaux derives de benzimidazoles, leur procede de preparation, leur application a titre de medicament, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de kdr
US7008953B2 (en) * 2003-07-30 2006-03-07 Agouron Pharmaceuticals, Inc. 3, 5 Disubstituted indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation

Also Published As

Publication number Publication date
NL1026761A1 (nl) 2005-02-01
MXPA06001193A (es) 2006-04-11
AU2004259531A1 (en) 2005-02-03
CO5650247A2 (es) 2006-06-30
PE20050330A1 (es) 2005-05-16
TNSN06038A1 (fr) 2007-10-03
PA8608201A1 (es) 2005-03-03
WO2005009997A1 (fr) 2005-02-03
IS8214A (is) 2005-12-30
JP2007500183A (ja) 2007-01-11
TW200521124A (en) 2005-07-01
ECSP066335A (es) 2006-07-28
US7008953B2 (en) 2006-03-07
EA200600123A1 (ru) 2006-06-30
AR045143A1 (es) 2005-10-19
US20060142345A1 (en) 2006-06-29
UY28442A1 (es) 2005-02-28
EP1658284A1 (fr) 2006-05-24
IL172924A0 (en) 2006-06-11
OA13196A (en) 2006-12-13
CA2532908A1 (fr) 2005-02-03
US20050026960A1 (en) 2005-02-03
JP3920914B2 (ja) 2007-05-30
NL1026761C2 (nl) 2005-10-18
MA27937A1 (fr) 2006-06-01
KR20060030914A (ko) 2006-04-11
BRPI0413051A (pt) 2006-10-17

Similar Documents

Publication Publication Date Title
NO20060319L (no) 3,5-disubstituerte indazolforbindelser, farmasoytiske blandinger og fremgangsmater for a mediere eller inhibere celleproliferasjon
WO2001053268A3 (fr) Composes d'indazole, compositions pharmaceutiques, et methodes destines a la mediation ou a l'inhibition de la proliferation cellulaire
TWI262914B (en) Compounds and pharmaceutical compositions for inhibiting protein kinases
WO2001002369A3 (fr) Composes d'indazole et compositions pharmaceutiques inhibant les proteines kinases, et procedes d'utilisation de ceux-ci
EA200500811A1 (ru) 2-(1h-индазол-6-иламино)бензамидные соединения как ингибиторы протеинкиназ, полезные для лечения офтальмологических заболеваний
YU85601A (sh) Diaminotiazoli i njihova upotreba za inhibiranje proteinskih kinaza
WO2006120573A3 (fr) N-oxydes heterocycliques utilises comme inhibiteurs de la proteine kinase lors d'une reduction selective dans un environnement hypoxique
NO20070049L (no) Pyrrolotriazinderivater anvendelig for behandling av hyperproliferative forstyrrelser og sykdommer assosiert med angiogenese
MXPA02012272A (es) Compuestos heterociclicos que son inhibidores de la enzima dipeptidilpeptidasa-iv.
NO20045677L (no) Inhibitorer av JAK- og CDK2-proteinkinaser
CY1108146T1 (el) ΑΝΑΣΤΟΛΕΙΣ ΤΗΣ β-ΑΜΙΝΟ-ΕΤΕΡΟΚΥΚΛΙΚΗΣ-ΔΙΠΕΠΤΙΔΥΛΙΚΗΣ ΠΕΠΤΙΔΑΣΗΣ ΓΙΑ ΤΗΝ ΑΓΩΓΗ Ή ΠΡΟΛΗΨΗ ΤΟΥ ΔΙΑΒΗΤΗ
NO20073615L (no) 3, 5-disubstituert og 3, 5, 7-trisubstituert-3H-oksazolo og 3H-tiazolo [4,5-d]pyrimidin-2-on forbindelser og prodrug derav
ATE473980T1 (de) Triazolopyridazine als proteinkinase-inhibitoren
DE60308699D1 (en) 2-phenylamino-4-trifluoromethyl-5-(benzyl- oder pyridin-4-ylmethyl)carbamoylpyrimidin-derivate als selektive cb2 cannabinoid-rezeptor modulatoren
ATE530184T1 (de) Piperazinon-verbindungen als tumor- und krebsbekämpfende wirkstoffe
WO2006057945A3 (fr) Derives pyridyle 2,3,4,6-substitues utiles comme inhibiteurs de la beta-secretase pour le traitement de la maladie d'alzheimer
BR0314783A (pt) Pirróis 3,4-dissubstituìdos e seu uso no tratamento de doenças inflamatórias
EA200300442A1 (ru) Способы и композиции для лечения воспалительных заболеваний
BR0314180A (pt) Aminoéteres substituìdos para o tratamento da doença de alzheimer
DE602004019500D1 (en) 4-substituirte-5-cyano-1h-pyrimidin-6-(th)iones als als gsk-3-hemmer
NO20002408L (no) 5-HT1F antagonister
NO20030021D0 (no) Heterosykliske forbindelser som er inhibitorer for enzymet DPP-IV
Anand et al. Discovery of Small‐Molecule Inhibitors Targeting Progranulin‐Sortilin: An in‐silico Approach Using Molecular Docking, Molecular Dynamics Simulations, and DFT Studies
Reigan Prodrugs of Thymidine Phosphorylase Inhibitors for Xanthine Oxidase Biotransformation
DOP2004000953A (es) Compuestos de indazol 3,5-disustituidos, composiciones farmaceuticas y metodos para intervenir en o inhibir la proliferacion celular.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application